$ASND Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $1.94 up 312.77% YoY
• Reported revenue of $418.71M up 67.01% YoY
• Ascendis Pharma expects full-year 2026 cash flow from operating activities of at least 600M; no revenue, margin, or earnings guidance was provided in the release.